不同剂量瑞舒伐他汀联合通心络胶囊治疗冠心病合并高脂血症患者的疗效观察

Therapeutic Effect of Different Doses of Rosuvastatin Combined with Tongxinluo Capsule on Patients with Coronary Heart Disease Complicated with Hyperlipidemia

目的:探讨不同剂量瑞舒伐他汀联合通心络胶囊治疗冠心病合并高脂血症患者的疗效。方法:按照随机数字表法将2017年4月至2018年5月内蒙古医科大学附属医院接诊的120例冠心病合并高脂血症患者分为低剂量联合组(5 mg瑞舒伐他汀+通心络胶囊)、中剂量联合组(10 mg瑞舒伐他汀+通心络胶囊)、高剂量联合组(20 mg瑞舒伐他汀+通心络胶囊),每组各40例,三组均治疗12周。比较三组患者的血脂指标、治疗效果、血清炎症因子水平,观察三组患者用药期间不良反应发生情况。结果:高剂量联合组、中剂量联合组治疗总有效率高于低剂量联合组(P<0.05)。治疗后,高剂量联合组、中剂量联合组的总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平低于低剂量联合组,高密度脂蛋白胆固醇(HDL-C)水平高于低剂量联合组(P<0.05)。治疗后三组患者的血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)水平随着剂量的升高而降低(P<0.05)。低、中、高剂量联合组不良反应发生率比较无统计学差异(P>0.05)。结论:采用10 mg和20 mg的瑞舒伐他汀联合通心络胶囊治疗冠心病合并高脂血症疗效确切,可有效改善患者血脂水平,无严重不良反应发生,且对炎症因子的改善效果成剂量依赖性,医师可根据临床实际选择用药剂量。

Objective: To explore the therapeutic effect of diffeent doses of rosuvastatin combined with Tongxinluo capsule on patients with coronary heart disease complicated with hyperlipidemia. Methods: According to the random number table method, 120 patients with coronary heart disease and hyperlipidemia admitted to the Affiliated Hospital of Inner Mongolia Medical University from April 2017 to May 2018 were divided into low-dose combination group(5 mg rosuvastatin + Tongxinluo capsule), medium-dose combination group(10 mg rosuvastatin + Tongxinluo capsule), high-dose combination group(20 mg rosuvastatin + Tongxinluo capsule).There were 40 cases in each group. The three groups were treated for 12 weeks. The blood lipid indexes, therapeutic effect, serum inflammatory factor levels in the three groups were compared. The adverse reactions during the three groups were observed. Results: The total effective rates in the high-dose, medium-dose combination group were higher than that in the low-dose combined group(P<0.05).After treatment, the levels of total cholesterol(TC), triglyceride(TG) and low density lipoprotein cholesterol(LDL-C) in the high-dose combination group and the medium-dose combination group were lower than those in the low-dose combination group, and the levels of high density lipoprotein cholesterol(HDL-C) were higher than those in the low-dose combination group(P<0.05). After treatment,the levels of serum high sensitivity C reactive protein(hs-CRP), tumor necrosis factor-α(TNF-α) and interferon-γ(IFN-γ) in the three groups decreased with the increase of dosage(P<0.05). There were no significant differences in the incidence of adverse reactions in the low-dose, medium-dose and high-dose combination group(P >0.05). Conclusion: 10 mg and 20 mg of rosuvastatin combined with Tongxinluo capsule in the treatment of coronary heart disease with hyperlipidemia is effective, can effectively improve blood lipid levels,there is no serious adverse reactions, and the improvement of inflammatory factors is dose dependent, physicians can choose the dosage according to clinical practice.